Shilpa Medicare Limited
All news and filings related to Shilpa Medicare Limited.
View all news & filings- Medium impact
NCLT Admits Insolvency Plea Against Shilpa Medicare Subsidiary FTF Pharma
NCLT admitted an insolvency application against FTF Pharma, a wholly-owned subsidiary of Shilpa Medicare. The application was filed by Immacule Lifesciences for an alleged operational debt of ₹2.18 crore. The NCLT ordered the commencement of Corporate Insolvency Resolution Process (CIRP) against FTF Pharma.
Read the summary - Low impact
Shilpa Medicare Announces 39th AGM on Sep 11, 2026; Annual Report for FY26 Released
Shilpa Medicare Limited will hold its 39th AGM on September 11, 2026, via VC/OAVM. The Annual Report for FY25-26 and AGM Notice have been dispatched and are available online. The cut-off date for voting is September 04, 2026, with remote e-voting from September 7-10, 2026.
Read the summary - Medium impact
Shilpa Medicare Initiates Voluntary Recall of 27,923 Vials of Chemotherapy Drug in US
Shilpa Medicare is voluntarily recalling 27,923 vials of Pemetrexed Injection in the US due to atypical discoloration. The recall, initiated on July 29, 2026, is classified as Class II by the US FDA. The company foresees no material financial or operational impact.
Read the summary - Low impact
Shilpa Medicare: TDS Communication for Final Dividend on 17 Aug 2026
Shilpa Medicare announced TDS procedures for its Re. 0.60 per share final dividend, recommended on May 22, 2026. Record date is September 4, 2026, and AGM is September 11, 2026. Shareholders must submit updated details and required tax documents by September 2, 2026, to ensure correct TDS application for resident and non-resident shareholders.
Read the summary - Low impact
Shilpa Medicare Announces 39th AGM on Sep 11, 2026, Recommends Final Dividend
Shilpa Medicare Limited will hold its 39th AGM on September 11, 2026. The company recommended a final dividend of Re. 0.60 per share for FY26. The record date for dividend entitlement is September 4, 2026. Remote e-voting will be open from September 7 to September 10, 2026.
Read the summary - High impact
Shilpa Medicare Q1 FY27: Highest Ever Revenue & EBITDA, PAT Surges 115%
Shilpa Medicare reported record Q1 FY27 revenue of ₹469 cr (up 43% YoY) and EBITDA of ₹139 cr (up 42% YoY). PAT surged 115% YoY to ₹101 cr. The company's credit rating was upgraded to AA-. Key growth drivers include API, Formulation, and Biologics divisions. Management expects continued robust growth and improved margins.
Read the summary - Low impact
Shilpa Medicare Limited Uploads Q1FY27 Conference Call Recording
Shilpa Medicare Limited has uploaded the audio recording of its Q1 FY2026-27 conference call, held on August 5, 2026. The recording is accessible on the company's website. This announcement follows a prior intimation about the call.
Read the summary - High impact
Shilpa Medicare Q1FY27 Revenue Surges 43% to ₹469 Crore, EBITDA Up 42%
Shilpa Medicare reported a 43% YoY revenue growth to ₹469 crore and a 42% YoY EBITDA increase to ₹139 crore for Q1FY27. PAT surged 115% YoY to ₹101 crore. Growth was driven by API, Formulations, and Biologics segments. The company also noted a credit rating upgrade to AA-.
Read the summary - Low impact
Shilpa Medicare sets Sept 4, 2026, as Record Date for Final Dividend Payment
Shilpa Medicare Limited has fixed September 4, 2026, as the Record Date for its final dividend for FY 2025-26. The AGM, where the dividend will be proposed for approval, is scheduled for September 11, 2026.
Read the summary - High impact
Shilpa Medicare Q1 FY27 Unaudited Results: Profit Rises, Director Re-appointment Approved
Shilpa Medicare reported strong Q1 FY27 results with standalone net profit at ₹6,492 lakhs and consolidated net profit at ₹10,088 lakhs. The Board approved the re-appointment of Mr. Sharath Reddy Kalakota as Whole-time Director. Shilpa Biocare plans to invest up to EUR 7 million in Gate2Brain. The 39th AGM is scheduled for September 11, 2026.
Read the summary - Medium impact
Shilpa Medicare Appoints Dr. Uday N. Harle as CEO of Shilpa Biologicals
Shilpa Medicare Limited announced the appointment of Dr. Uday N. Harle as CEO of its subsidiary, Shilpa Biologicals Private Limited, effective August 3, 2026. Dr. Harle has 24 years of experience in the biopharmaceutical industry, with a focus on biologics and biosimilars.
Read the summary - Medium impact
Shilpa Medicare to Announce Q1 FY27 Results on Aug 05, 2026
Shilpa Medicare Limited will announce its Q1 FY27 results for the quarter ended June 30, 2026, on August 05, 2026. The company will host an earnings conference call on the same day at 16:00 hrs.
Read the summary - Medium impact
Shilpa Biologicals Pvt. Ltd. Gets IND A+/Stable Rating for Bank Loans
Shilpa Medicare's material subsidiary, Shilpa Biologicals Private Limited, has received a credit rating of IND A+/Stable for its bank loan facilities worth ₹1,250 million (₹125 crore) from India Ratings and Research Pvt. Ltd. An IND A1+ rating was also assigned.
Read the summary - Medium impact
Shilpa Medicare Subsidiary CEO Resigns Due to Personal Commitments
Dr. Sridevi Khambhampaty resigned as CEO of Shilpa Biologicals Private Limited, a subsidiary of Shilpa Medicare Limited. Her resignation is effective July 15, 2026, due to personal commitments. The resignation letter was submitted on April 15, 2026.
Read the summary - Low impact
Shilpa Medicare Files SEBI Compliance Certificate for Q1 FY27
Shilpa Medicare Limited submitted a compliance certificate under SEBI regulations for the quarter ended June 30, 2026. The certificate from the Registrar and Share Transfer Agent confirms dematerialization/rematerialization details have been furnished to stock exchanges.
Read the summary - Medium impact
Shilpa Medicare's Subsidiary Partners with Orion Corp for IV Nivolumab Biosimilar in Europe
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has partnered with Finland-based Orion Corporation for the co-development and supply of an IV Nivolumab biosimilar for the European market. Shilpa will manufacture and supply the drug, while Orion will handle registration, marketing, and distribution in Europe. The deal aims to increase patient access to the cancer immunotherapy.
Read the summary - High impact
Shilpa Medicare subsidiary commissions India's integrated ADC Drug Substance GMP Facility
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. This facility offers integrated end-to-end ADC Drug Substance development and manufacturing, positioning Shilpa as a CDMO partner for global pharmaceutical and biotech companies.
Read the summary - Medium impact
Shilpa Medicare Ltd. Shareholders Approve Shifting Registered Office Via Postal Ballot
Shilpa Medicare Limited shareholders approved the shifting of the company's registered office via postal ballot. The special resolution passed with 99.99% of votes in favour. The e-voting period concluded on June 22, 2026.
Read the summary - Medium impact
Shilpa Medicare's subsidiary partners with Gate2Brain for brain cancer therapy
Shilpa Medicare's subsidiary, Shilpa Biocare, has formed a strategic equity partnership with Gate2Brain, acquiring a 30.4% stake for Euro 7 million (approx. ₹63 crore). The partnership aims to advance G2B-002, a brain cancer therapy, with first-in-human trials expected by FY28. Shilpa will provide CMC, manufacturing, and regulatory support.
Read the summary - Low impact
Shilpa Medicare Unit VI Undergoes USFDA Inspection, Receives 5 Procedural Observations
Shilpa Medicare's Unit VI in Bengaluru was inspected by the USFDA from May 25-29, 2026. The inspection resulted in 5 procedural observations on Form 483, with no repeat issues or data integrity concerns. The company expects no material impact on operations or supplies.
Read the summary - High impact
Shilpa Medicare Limited Transcripts Q4 FY26 Conference Call
Shilpa Medicare reported record Q4 FY26 revenues of ₹439 crore, up 30% YoY, and full-year revenues of ₹1,549 crore, up 18%. EBITDA grew 40% QoQ to ₹121 crore and 30% YoY to ₹445 crore for the full year, with margins improving to 28% and 29% respectively. The company is building a differentiated pharma platform across APIs, formulations, biologics, and CDMO.
Read the summary - Low impact
Shilpa Medicare Ltd. Publishes Postal Ballot Notice, Announces Dividend
Shilpa Medicare Limited announced its Postal Ballot notice published on May 23, 2026, with e-voting from May 24 to June 22, 2026. The company recommended a final dividend of ₹0.60 per equity share for FY 2025-26. Financials for Q4 FY26 show total income of ₹20,111 lakhs and net profit of ₹7,096 lakhs.
Read the summary - Low impact
Shilpa Medicare: Q4 FY26 Earnings Conference Call Recording Available
Shilpa Medicare Limited has made the audio recording of its Q4 FY26 Earnings Conference Call, held on May 22, 2026, available on its website. The call was previously intimated on May 14, 2026.
Read the summary - High impact
Shilpa Medicare FY26 Revenue Surges 18% to ₹1,549 Crore, EBITDA Grows 30%
Shilpa Medicare reported FY26 revenue of ₹1,549 crore, up 18% YoY, and EBITDA of ₹445 crore, up 30% YoY. Q4 FY26 revenue was ₹439 crore (up 30% YoY) and EBITDA was ₹121 crore (up 40% YoY). Adjusted PAT for Q4 FY26 was ₹87 crore, a 147% YoY increase. The company highlighted strong growth across API, Formulation, and Biologics segments.
Read the summary - Medium impact
Shilpa Medicare Seeks Shareholder Approval to Shift Registered Office to Maharashtra
Shilpa Medicare Limited is seeking shareholder approval via postal ballot to shift its registered office from Karnataka to Maharashtra. E-voting will be open from May 24 to June 22, 2026. The relocation aims to leverage Mumbai's status as a financial hub for business and administrative advantages.
Read the summary - Medium impact
Shilpa Medicare Recommends ₹0.60 Dividend; Subsidiaries Invest ₹4.44 Cr in Renewable Energy
Shilpa Medicare recommended a final dividend of ₹0.60 per share for FY26. Its subsidiaries will invest ₹4.44 Crore for a 28% stake in Neo Green Power Project Private Limited, aiming to secure captive power. The company also approved shifting its registered office to Maharashtra.
Read the summary - Medium impact
Shilpa Medicare Board Approves FY26 Audited Results, Recommends Dividend, and Approves Subsidiary Investment
Shilpa Medicare's Board approved FY26 audited financials and recommended a dividend of ₹0.60 per share. Subsidiaries will invest ₹4.44 Crore for a 28% stake in Neo Green Power Project, aiming for completion by 15 June 2026. The company also approved shifting its registered office from Karnataka to Maharashtra.
Read the summary - Low impact
Shilpa Medicare to announce 4QFY26 results on May 22, 2026; Earnings call scheduled
Shilpa Medicare Limited will announce its 4QFY26 results on May 22, 2026. An earnings conference call is scheduled for the same day at 16:00 hrs. The company is an integrated pharmaceutical group with interests in APIs, formulations, and CDMO services.
Read the summary - Medium impact
Shilpa Medicare Appoints Dr. Vellaian Karuppiah as COO - Formulations
Shilpa Medicare Limited appointed Dr. Vellaian Karuppiah as Chief Operating Officer (COO) - Formulations, effective April 23, 2026. Dr. Karuppiah brings over 33 years of experience in the pharmaceutical industry, having held senior leadership roles at global companies. His appointment aims to strengthen operations and drive growth.
Read the summary - Low impact
Shilpa Medicare Limited: COO Dr. Jayant Karajgi Retires on April 22, 2026
Dr. Jayant Karajgi, Chief Operating Officer – Formulations at Shilpa Medicare Limited, has retired. His retirement is effective from April 22, 2026. He will also cease to be a Senior Management Personnel of the company.
Read the summary - Low impact
Shilpa Medicare Limited Clarifies Not a Large Corporate Under SEBI Framework
Shilpa Medicare Limited confirmed it is not a Large Corporate under SEBI guidelines as of March 31, 2025, reporting nil long-term borrowing. The company holds an A+ rating with a Positive Outlook from India Ratings & Research.
Read the summary - Low impact
Shilpa Medicare Files SEBI Compliance Certificate for Q4 FY26
Shilpa Medicare Limited submitted a certificate under SEBI regulations for the quarter ended March 31, 2026. The company's Registrar and Share Transfer Agent, Kfin Technologies Limited, confirmed that dematerialization/rematerialization details were furnished to stock exchanges.
Read the summary - Low impact
Shilpa Medicare Promoter Group Discloses Shareholding and Encumbrance for FY26
Shilpa Medicare's promoter group disclosed their shareholding and encumbrances for the year ended March 31, 2026. They hold 7,84,96,648 shares (40.13%). The disclosure includes details on pledged shares by individuals like Mr. Vishnukant Bhutada and Mr. Om Prakash Innani.
Read the summary - Low impact
Shilpa Medicare: Trading Window Closed for Q4FY26 Results from April 1
Shilpa Medicare's trading window will be closed from April 1, 2026, until 48 hours after the board meeting to approve Q4FY26 and annual audited financial results. Designated persons are restricted from trading during this period.
Read the summary - Medium impact
Shilpa Medicare's Merger with Subsidiary Shilpa Therapeutics Approved by NCLT
Shilpa Medicare Limited's merger with its wholly-owned subsidiary, Shilpa Therapeutics Private Limited, has been approved by the NCLT. The effective date will be upon filing the certified order with the Registrar of Companies. The company has provided undertakings regarding statutory dues and employee interests. The appointed date for the amalgamation is April 1, 2025.
Read the summary - Medium impact
Shilpa Medicare Subsidiary Signs Biosimilar Licensing Deal for Latin America
Shilpa Biologicals, a subsidiary of Shilpa Medicare, has signed a licensing agreement with SteinCares to commercialize a biosimilar in Latin America. SteinCares will handle registration and distribution, while Shilpa Biologicals will manage development and manufacturing. This deal marks Shilpa Biologicals' entry into the Latin American market.
Read the summary - Low impact
Shilpa Medicare Limited Announces Special Window for Share Transfer and Dematerialization
Shilpa Medicare Limited is offering a special window for transferring and dematerializing physical shares sold/purchased before April 1, 2019. The window is open for one year from February 5, 2026, to February 4, 2027. Transferred shares will be in demat mode with a one-year lock-in.
Read the summary - Medium impact
Shilpa Medicare partners NXI Therapeutics for autoimmune therapy development & manufacturing
Shilpa Medicare Limited entered a strategic partnership with NXI Therapeutics AG for developing and manufacturing novel therapies for autoimmune disorders. Shilpa will provide comprehensive development and manufacturing support. This is the third major international contract for Shilpa, strengthening its CDMO platform and long-term growth visibility.
Read the summary - Medium impact
Shilpa Medicare inks strategic deal with NXI Therapeutics AG for novel asset
Shilpa Medicare Limited has signed a binding agreement with NXI Therapeutics AG (Switzerland) for the development, manufacturing, and supply of a novel therapy targeting autoimmune and alloimmune disorders. The collaboration covers the full product lifecycle, from development to commercial manufacturing. This marks the third major international contract for Shilpa Medicare.
Read the summary - High impact
Shilpa Medicare Q3 FY26 Call Transcript Released; Highest Revenue & EBITDA Reported
Shilpa Medicare reported record Q3 FY26 revenue of ₹411 crore (up 28% YoY) and EBITDA of ₹115 crore (up 41% YoY). Key developments include commercialization of an NCE product, progress in API and Formulation pipelines, and advancements in Biologics. The company expects continued growth driven by its strategic focus on limited-competition products and integrated offerings.
Read the summary - Low impact
Shilpa Medicare Releases Q3 FY26 Earnings Call Recording
Shilpa Medicare Limited has uploaded the audio recording of its Q3 FY26 Earnings Conference Call, which took place on February 6, 2026. The recording is accessible on the company's investor relations webpage.
Read the summary - Medium impact
Shilpa Medicare Files First Transdermal Patch ANDA with USFDA for Rotigotine
Shilpa Medicare has filed its first transdermal patch ANDA for Rotigotine USP with the USFDA. The product is a generic version of Neupro®, targeting Restless Legs Syndrome and Parkinson's disease. The US market for Rotigotine is estimated at USD 112 million (approx. ₹929 crore).
Read the summary - High impact
Shilpa Medicare Q3 FY26 Revenue Up 28% to ₹411 Cr, EBITDA Grows 40%
Shilpa Medicare reported 3QFY26 consolidated revenue of ₹411 crore, up 28% YoY, and EBITDA of ₹115 crore, up 40% YoY. For 9MFY26, revenue was ₹1,110 crore (up 14% YoY) and EBITDA was ₹323 crore (up 26% YoY). The company launched a first-in-class NAFLD therapy in India and saw significant growth in its Formulations business.
Read the summary - Medium impact
Shilpa Medicare Approves Q3 FY26 Standalone & Consolidated Results; Reconstitutes Audit Committee
Shilpa Medicare Limited approved its unaudited standalone and consolidated financial results for Q3 FY26. Standalone net profit was ₹1,593.46 lakhs and consolidated net profit attributable to owners was ₹4,875.16 lakhs for the quarter. The company also reconstituted its Audit Committee, inducting Mr. Ashraf Allam.
Read the summary - Medium impact
Shilpa Medicare Q3 FY26 Standalone Profit Rs. 15.84 Cr, Consolidated Profit Rs. 48.75 Cr
Shilpa Medicare reported standalone net profit of ₹15.84 crore and consolidated net profit of ₹48.75 crore for Q3 FY26. The company also announced the induction of Mr. Ashraf Allam to its Audit Committee.
Read the summary - Low impact
Shilpa Medicare Board Approves Q3 FY26 Results and Audit Committee Reconstitution
Shilpa Medicare's Board approved Q3 FY26 unaudited standalone and consolidated financial results on February 6, 2026. The Audit Committee was reconstituted with the induction of Mr. Ashraf Allam as a member. The meeting concluded at 2:30 PM IST.
Read the summary - Low impact
Shilpa Medicare Announces 3Q FY26 Earnings Conference Call on Feb 6, 2026
Shilpa Medicare Limited will announce its 3Q FY26 results for the quarter ended December 31, 2025, on February 6, 2026. The company will also host its earnings conference call on the same day at 16:00 hrs. Details for joining the call are provided.
Read the summary - Medium impact
Shilpa Medicare Subsidiary's Biologic Gets FDA Orphan Drug Designation for Rare Blood Cancers
Shilpa Medicare's subsidiary, Shilpa Biologicals, and mAbTree Biologics received FDA Orphan Drug Designation for their biologic targeting rare blood cancers ET and PV. This designation offers incentives and market exclusivity, paving the way for future clinical trials.
Read the summary - Low impact
Shilpa Medicare Assigned ESG Score of 61.5 by SES ESG Research
Shilpa Medicare Limited received an ESG score of 61.5 from SES ESG Research Pvt Ltd. The rating is based on publicly available data for FY2025 and was independently prepared by the rating agency.
Read the summary - Low impact
Shilpa Medicare Subsidiary Koanna Healthcare Ceases to be Wholly Owned
Shilpa Medicare's subsidiary, Koanna Healthcare Canada Inc., allotted 2.84 crore equity shares for CAD 2,000 on Jan 14, 2026, to Steve N. Slilaty. Consequently, Koanna Healthcare is no longer a wholly owned subsidiary. The transaction has no impact on Shilpa Medicare's financials. Koanna Healthcare's contribution to last year's revenue was 0.03%.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio